Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Indevus Pharmaceuticals has announced the issuance of a US patent covering the company's approved product, Sanctura XR, a once-a-day formulation of trospium chloride which is indicated for the treatment of symptoms of an overactive bladder.
Subscribe to our email newsletter
The patent is licensed exclusively to the company by the patent’s assignee, Supernus Pharmaceuticals.
Based on calculations made by the US Patent and Trademark Office, the term of the patent is 20 years plus 89 days from its filing date of November 4, 2004, or February 1, 2025.